[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351020-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-351020-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","high-oncological-efficacy-of-bcg-maintenance-therapy-for-primary-high-grade-t1-urothelial-carcinoma-of-the-bladder","High Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder","","High-grade pT1 urothelial carcinoma (HG-T1 UC) is a non-muscle-invasive bladder cancer with high recurrence and progression risk, making maintenance intravesical therapy clinically important. This retrospective cohort study evaluated treatment patterns, efficacy, adverse-event incidence, and predictors of recurrence/progression in 204 patients treated at Toho University Sakura Medical Center between 2010 and 2021. Maintenance BCG therapy significantly prolonged recurrence-free survival versus other approaches, including in very high-risk cases, but adverse events occurred in 52.4% and dose reductions were needed in 59%. Dose reduction did not increase recurrence, while tumor multiplicity independently predicted recurrence.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-oncological-efficacy-of-bcg-maintenance-therapy-for-primary-high-grade-t1-urothelial-carcinoma-of-the-bladder/351020/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-oncological-efficacy-of-bcg-maintenance-therapy-for-primary-high-grade-t1-urothelial-carcinoma-of-the-bladder/351020.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study?","Question",{"text":63,"@type":64},"To evaluate treatment patterns, therapeutic efficacy, adverse-event incidence, and clinical predictors of recurrence and progression in patients with high-grade pT1 urothelial carcinoma of the bladder.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients were included, and what period were they treated?",{"text":68,"@type":64},"The retrospective cohort included 204 patients diagnosed with HG-pT1 UC who underwent TURBT at Toho University Sakura Medical Center between 2010 and 2021.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding maintenance BCG therapy?",{"text":72,"@type":64},"Maintenance BCG therapy was significantly associated with prolonged recurrence-free survival compared with other treatments, including among very high-risk patients.",{"name":74,"@type":61,"acceptedAnswer":75},"Did dose reductions during BCG maintenance affect recurrence rates?",{"text":76,"@type":64},"No. Recurrence rates did not significantly differ based on dose reduction or on the total number of BCG instillations; tumor multiplicity emerged as an independent risk factor for recurrence.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},351020,1790149439,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nHigh Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder  \nTakahide Noro 1, Naoto Kamiya 1, *, Naoki Ishitsuka 1, Rino Ikeda 1, Yuta Suzuki 1, Syota Iijima 1, Yuka Sugizaki 1, Takatoshi Somoto 1, Ryo Oka 1, Takanobu Utsumi 1, Takumi Endo 1, Nobuyuki Hiruta 2 and Hiroyoshi Suzuki 1  \nAcademic Editors: Susanne Vahr Lauridsen and Bente Thoft Jensen  \nReceived: 6 January 2026  \nRevised: 3 February 2026  \nAccepted: 4 February 2026  \nPublished: 6 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan; [takahide.noro@med.toho-u.ac.jp](takahide.noro@med.toho-u.ac.jp) (T.N.); [naoki.ishitsuka@med.toho-u.ac.jp](naoki.ishitsuka@med.toho-u.ac.jp) (N.I.); [rino.ikeda@med.toho-u.ac.jp](rino.ikeda@med.toho-u.ac.jp) (R.I.); [yuta.suzuki@med.toho-u.ac.jp](yuta.suzuki@med.toho-u.ac.jp) (Y.S.); [shouta.iijima@med.toho-u.ac.jp](shouta.iijima@med.toho-u.ac.jp) (S.I.); [yuuka.kizuki@med.toho-u.ac.jp](yuuka.kizuki@med.toho-u.ac.jp) (Y.S.); [takatoshi.soumoto@med.toho-u.ac.jp](takatoshi.soumoto@med.toho-u.ac.jp) (T.S.); [ryou.oka@med.toho-u.ac.jp](ryou.oka@med.toho-u.ac.jp) (R.O.); [takanobu.utsumi@med.toho-u.ac.jp](takanobu.utsumi@med.toho-u.ac.jp) (T.U.); [takumi.endou@med.toho-u.ac.jp](takumi.endou@med.toho-u.ac.jp) (T.E.); [hiroyoshi.suzuki@med.toho-u.ac.jp](hiroyoshi.suzuki@med.toho-u.ac.jp) (H.S.)  \n2 Department of Surgical Pathology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi 285-8741, Chiba, Japan; [nhr@med.toho-u.ac.jp](nhr@med.toho-u.ac.jp)  \n* [Correspondence: naoto.kamiya@med.toho-u.ac.jp](Correspondence: naoto.kamiya@med.toho-u.ac.jp); Tel.: +81-43-462-8811  \nSimple Summary  \nHigh-grade pT1 urothelial carcinoma (HG-T1 UC) is a non-muscle-invasive bladder cancer with a high risk of recurrence and progression. We retrospectively analyzed 204 patients treated at Toho University Sakura Medical Center to evaluate real-world outcomes of intravesical therapies, mainly Bacillus Calmette–Guérin (BCG) and intravesical chemotherapy. Maintenance BCG therapy significantly prolonged recurrence-free survival compared with other treatments, even in very high-risk cases. However, over half of the patients experienced adverse events, and dose reductions were required in approximately 60% of them. These reductions did not increase recurrence rates. Tumor multiplicity was identified as an independent risk factor for recurrence. This study clarifies the efficacy and challenges of BCG maintenance therapy. For the primary treatment of HG-T1 UC of the bladder, intravesical BCG maintenance therapy should be implemented, incorporating flexible dose reductions and treatment interruptions to effectively manage adverse events.  \nAbstract  \nBackground: In high-risk non-muscle-invasive bladder cancer (NMIBC), adjuvant therapies, such as intravesical Bacillus Calmette–Guérin (BCG) instillation, are widely employed; however, BCG treatment poses challenges due to potential adverse effects and ongoing supply limitations. This study aimed to evaluate treatment patterns, therapeutic efficacy, incidence of adverse events, and clinical predictors of recurrence and progression in patients with high-grade pT1 urothelial carcinoma (HG-T1 UC) of the bladder. Methods: This retrospective cohort study included 204 patients diagnosed with HG-pT1 UC who underwent transurethral resection of bladder tumor (TURBT) at Toho University Sakura Medical Center between 2010 and 2021 . Clinical data encompassing treatment modalities (BCG or intravesical chemotherapy), complications, and oncological outcomes were collected. Recurrence-Free Survival (RFS), Progression-Free Survival, and Cancer-Specific Survival were analyzed usi","cbCaiiFBfhbtdqRo","https://ap.wps.com/l/cbCaiiFBfhbtdqRo","pdf",699067,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Epidemiology and risk profile\n## Rationale for intravesical therapy","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To evaluate treatment patterns, therapeutic efficacy, adverse-event incidence, and clinical predictors of recurrence and progression in patients with high-grade pT1 urothelial carcinoma of the bladder.\"},{\"question\":\"How many patients were included, and what period were they treated?\",\"answer\":\"The retrospective cohort included 204 patients diagnosed with HG-pT1 UC who underwent TURBT at Toho University Sakura Medical Center between 2010 and 2021.\"},{\"question\":\"What were the key findings regarding maintenance BCG therapy?\",\"answer\":\"Maintenance BCG therapy was significantly associated with prolonged recurrence-free survival compared with other treatments, including among very high-risk patients.\"},{\"question\":\"Did dose reductions during BCG maintenance affect recurrence rates?\",\"answer\":\"No. Recurrence rates did not significantly differ based on dose reduction or on the total number of BCG instillations; tumor multiplicity emerged as an independent risk factor for recurrence.\"}]","High Oncological Efficacy of BCG Maintenance Therapy for Primary High-Grade T1 Urothelial Carcinoma of the Bladder | PDF",1790092296,33,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0da660e5e0f0ae40c0a345159c724ff3.webp",983,1390,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d792122e3a70825e00f52564e861931.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d6f72964d6481a5bf5b1e065b497c7c.webp",981,1387,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e302706a342aa5235277d5144bf75cbe.webp",980,1385]